Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.
about
Trace amine-associated receptors as emerging therapeutic targetsUbiquitination of CXCR7 controls receptor traffickingAntipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanismsMultiple D2 heteroreceptor complexes: new targets for treatment of schizophreniaTrace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsRegulation of G protein-coupled receptors by allosteric ligandsCYP2D6 polymorphisms and their influence on risperidone treatmentThe protein arginine methyltransferase PRMT5 promotes D2-like dopamine receptor signalingA role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health(-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signalingDopamine receptors - IUPHAR Review 13Altered ratio of D1 and D2 dopamine receptors in mouse striatum is associated with behavioral sensitization to cocaineImpedance responses reveal β₂-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profilesTemporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brainUnique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in RatsIn Vitro and In Vivo Characterization of the Alkaloid NuciferineEffects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic MiceDeletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategyActivation of GABA(B) receptors inhibits protein kinase B/glycogen synthase kinase 3 signaling.The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatmentD(2) receptors receive paracrine neurotransmission and are consistently targeted to a subset of synaptic structures in an identified neuron of the crustacean stomatogastric nervous system.Novel, gel-free proteomics approach identifies RNF5 and JAMP as modulators of GPCR stability.Viagra for your synapses: Enhancement of hippocampal long-term potentiation by activation of beta-adrenergic receptors.Ligand-directed signalling at beta-adrenoceptorsPartially deglycosylated equine LH preferentially activates beta-arrestin-dependent signaling at the follicle-stimulating hormone receptor.Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptorClozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of AktThe role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulationClassics in Chemical Neuroscience: Aripiprazole.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Beyond desensitization: physiological relevance of arrestin-dependent signaling.Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapineII. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.ARRB1/β-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia.Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.
P2860
Q22242286-21838A21-103C-4D15-B167-22C7D751E30AQ24310278-DFB73F23-B0C8-49A5-9D4C-532D2068FCC6Q26745506-29A14201-1371-40DB-930F-5A0695C3D511Q26747736-BC4D9622-8822-4B5F-862F-CC42DD3C0D09Q26752602-C4DD5AB6-C238-410B-A0AB-01BAA48B1CACQ26864384-CA94ABD0-1632-45FD-B89D-93F311ABF482Q28079227-239F77D3-E51E-484E-8CDC-95FE649C87C9Q28115067-96EF9C87-CFB9-449B-8E1A-7DD7A6A6704FQ28118906-D5917FEB-14FA-4182-9369-B013767D271AQ28248215-93AED48D-4079-4F41-9030-7492D7160610Q28256783-C4146D30-DADA-425F-868B-A2633973C2A9Q28474330-892532A3-FCA2-409C-A0C2-4FF11633C5F9Q28478728-83DF0EC3-46F4-4C83-B21A-A8D845293458Q28543523-C0C1CC68-1B6D-4C41-B32B-8158005D5E7AQ28546441-3138B249-A311-41FD-8AF3-D19081EC3B15Q28550683-0EF8CFCD-D679-422D-B7B5-0FF71536923FQ30364693-1F4E17B6-4BDC-4860-9B5A-B7373CC534A7Q30453635-701F3081-6103-469C-9325-1299124BE1ADQ30458926-50182030-C821-4F3B-8878-341D3F7374AAQ30458968-8A54CD1D-6C9C-46BB-B7C0-6AE4503E58BDQ30506209-A9416204-B731-431C-8758-9A9D4108577DQ30574206-2A82F8A4-2987-4ABE-919A-1BC8A5CD08F1Q33669652-EE4866A1-5AB5-42AF-89A9-1CBCE25A7633Q33678921-26A047DA-1C7D-4C32-BA0D-16A5C93DF443Q33730592-B3018384-13C4-4703-B6B9-9C6FC3F7E8EBQ33735942-DCED4006-5ECD-4508-949F-B7BEB4BA3FF6Q33742774-1F4D6344-99E9-4B18-BA5B-DDF685F20AFAQ33764262-56908C84-63FA-4CE1-B416-D3693C7A200EQ33841893-8EA97FAC-081E-4CD9-83E7-AA63C497F9B0Q33866125-86524276-A715-4290-922F-57DCBDFA41BDQ33890786-10D5B5AA-C721-4DC5-B4B7-8CDC838D8507Q33890802-288CD748-9461-4BBA-98B0-A8C90D82BC87Q34007358-F276F53F-1EFF-413F-9CD4-8A90C0FC160AQ34094008-74B40812-423D-4EF1-A3EE-6BE251DE8A86Q34129991-4B744084-E164-4E26-84F5-11CBA0CCE8DDQ34210759-AEF61971-C7EC-435A-A481-9794DF9BAF83Q34227284-17AB62A7-5B69-4AEE-B255-D329B4E08822Q34274859-46E4A50E-7C51-4813-9EF0-E6BEAA131708Q34388776-168577E6-F47A-486C-B22A-AE448820B24FQ34423308-03231E10-DA30-4DB5-B1B6-920F7F3151A4
P2860
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Antagonism of dopamine D2 rece ...... ally effective antipsychotics.
@en
type
label
Antagonism of dopamine D2 rece ...... ally effective antipsychotics.
@en
prefLabel
Antagonism of dopamine D2 rece ...... ally effective antipsychotics.
@en
P2093
P2860
P50
P356
P1476
Antagonism of dopamine D2 rece ...... cally effective antipsychotics
@en
P2093
Ali Salahpour
Marc G Caron
Michael Didriksen
Valentina Ghisi
P2860
P304
13656-13661
P356
10.1073/PNAS.0803522105
P407
P577
2008-09-03T00:00:00Z